Literature DB >> 25065977

Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.

Feng Gao1, Mattia Bonsignori2, Hua-Xin Liao2, Amit Kumar2, Shi-Mao Xia2, Xiaozhi Lu2, Fangping Cai2, Kwan-Ki Hwang2, Hongshuo Song2, Tongqing Zhou3, Rebecca M Lynch3, S Munir Alam2, M Anthony Moody2, Guido Ferrari2, Mark Berrong2, Garnett Kelsoe2, George M Shaw4, Beatrice H Hahn4, David C Montefiori2, Gift Kamanga5, Myron S Cohen6, Peter Hraber7, Peter D Kwong3, Bette T Korber7, John R Mascola3, Thomas B Kepler8, Barton F Haynes9.   

Abstract

Development of strategies for induction of HIV-1 broadly neutralizing antibodies (bnAbs) by vaccines is a priority. Determining the steps of bnAb induction in HIV-1-infected individuals who make bnAbs is a key strategy for immunogen design. Here, we study the B cell response in a bnAb-producing individual and report cooperation between two B cell lineages to drive bnAb development. We isolated a virus-neutralizing antibody lineage that targeted an envelope region (loop D) and selected virus escape mutants that resulted in both enhanced bnAb lineage envelope binding and escape mutant neutralization-traits associated with increased B cell antigen drive. Thus, in this individual, two B cell lineages cooperated to induce the development of bnAbs. Design of vaccine immunogens that simultaneously drive both helper and broadly neutralizing B cell lineages may be important for vaccine-induced recapitulation of events that transpire during the maturation of neutralizing antibodies in HIV-1-infected individuals.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25065977      PMCID: PMC4150607          DOI: 10.1016/j.cell.2014.06.022

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  50 in total

Review 1.  HIV vaccine design: the neutralizing antibody conundrum.

Authors:  Leonidas Stamatatos
Journal:  Curr Opin Immunol       Date:  2012-05-15       Impact factor: 7.486

2.  Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop.

Authors:  Penny L Moore; Elin S Gray; Daniel Sheward; Maphuti Madiga; Nthabeleng Ranchobe; Zhong Lai; William J Honnen; Molati Nonyane; Nancy Tumba; Tandile Hermanus; Sengeziwe Sibeko; Koleka Mlisana; Salim S Abdool Karim; Carolyn Williamson; Abraham Pinter; Lynn Morris
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

Review 3.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 4.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

Authors:  Peter D Kwong; John R Mascola
Journal:  Immunity       Date:  2012-09-21       Impact factor: 31.745

5.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals.

Authors:  Johannes F Scheid; Hugo Mouquet; Niklas Feldhahn; Michael S Seaman; Klara Velinzon; John Pietzsch; Rene G Ott; Robert M Anthony; Henry Zebroski; Arlene Hurley; Adhuna Phogat; Bimal Chakrabarti; Yuxing Li; Mark Connors; Florencia Pereyra; Bruce D Walker; Hedda Wardemann; David Ho; Richard T Wyatt; John R Mascola; Jeffrey V Ravetch; Michel C Nussenzweig
Journal:  Nature       Date:  2009-03-15       Impact factor: 49.962

6.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.

Authors:  Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

7.  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors:  Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

8.  Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.

Authors:  David C Montefiori; Chitraporn Karnasuta; Ying Huang; Hasan Ahmed; Peter Gilbert; Mark S de Souza; Robert McLinden; Sodsai Tovanabutra; Agnes Laurence-Chenine; Eric Sanders-Buell; M Anthony Moody; Mattia Bonsignori; Christina Ochsenbauer; John Kappes; Haili Tang; Kelli Greene; Hongmei Gao; Celia C LaBranche; Charla Andrews; Victoria R Polonis; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Steve G Self; Phillip W Berman; Donald Francis; Faruk Sinangil; Carter Lee; Jim Tartaglia; Merlin L Robb; Barton F Haynes; Nelson L Michael; Jerome H Kim
Journal:  J Infect Dis       Date:  2012-05-25       Impact factor: 5.226

9.  Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Authors:  Constantinos Kurt Wibmer; Jinal N Bhiman; Elin S Gray; Nancy Tumba; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris; Penny L Moore
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  BeAtMuSiC: Prediction of changes in protein-protein binding affinity on mutations.

Authors:  Yves Dehouck; Jean Marc Kwasigroch; Marianne Rooman; Dimitri Gilis
Journal:  Nucleic Acids Res       Date:  2013-05-30       Impact factor: 16.971

View more
  167 in total

Review 1.  HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth.

Authors:  Priyamvada Acharya; Sabrina Lusvarghi; Carole A Bewley; Peter D Kwong
Journal:  Expert Opin Ther Targets       Date:  2015-02-27       Impact factor: 6.902

Review 2.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

Review 3.  Memory B cells.

Authors:  Tomohiro Kurosaki; Kohei Kometani; Wataru Ise
Journal:  Nat Rev Immunol       Date:  2015-02-13       Impact factor: 53.106

Review 4.  The evolution within us.

Authors:  Sarah Cobey; Patrick Wilson; Frederick A Matsen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

5.  Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Authors:  Ema T Crooks; Keiko Osawa; Tommy Tong; Samantha L Grimley; Yang D Dai; Robert G Whalen; Daniel W Kulp; Sergey Menis; William R Schief; James M Binley
Journal:  Virology       Date:  2017-03-06       Impact factor: 3.616

Review 6.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

Review 7.  How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.

Authors:  Marie Pancera; Anita Changela; Peter D Kwong
Journal:  Curr Opin HIV AIDS       Date:  2017-05       Impact factor: 4.283

Review 8.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

9.  Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.

Authors:  Daniel T MacLeod; Nancy M Choi; Bryan Briney; Fernando Garces; Lorena S Ver; Elise Landais; Ben Murrell; Terri Wrin; William Kilembe; Chi-Hui Liang; Alejandra Ramos; Chaoran B Bian; Lalinda Wickramasinghe; Leopold Kong; Kemal Eren; Chung-Yi Wu; Chi-Huey Wong; Sergei L Kosakovsky Pond; Ian A Wilson; Dennis R Burton; Pascal Poignard
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

Authors:  Till Schoofs; Florian Klein; Malte Braunschweig; Edward F Kreider; Anna Feldmann; Lilian Nogueira; Thiago Oliveira; Julio C C Lorenzi; Erica H Parrish; Gerald H Learn; Anthony P West; Pamela J Bjorkman; Sarah J Schlesinger; Michael S Seaman; Julie Czartoski; M Juliana McElrath; Nico Pfeifer; Beatrice H Hahn; Marina Caskey; Michel C Nussenzweig
Journal:  Science       Date:  2016-05-05       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.